145 related articles for article (PubMed ID: 23661613)
1. Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study.
Weinmann S; Van Den Eeden SK; Haque R; Chen C; Richert-Boe K; Schwartzman J; Gao L; Berry DL; Kallakury BV; Alumkal JJ
Prostate; 2013 Sep; 73(13):1371-7. PubMed ID: 23661613
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ
Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539
[TBL] [Abstract][Full Text] [Related]
3. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
5. Antibody-based detection of ERG rearrangement-positive prostate cancer.
Park K; Tomlins SA; Mudaliar KM; Chiu YL; Esgueva R; Mehra R; Suleman K; Varambally S; Brenner JC; MacDonald T; Srivastava A; Tewari AK; Sathyanarayana U; Nagy D; Pestano G; Kunju LP; Demichelis F; Chinnaiyan AM; Rubin MA
Neoplasia; 2010 Jul; 12(7):590-8. PubMed ID: 20651988
[TBL] [Abstract][Full Text] [Related]
6. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
[TBL] [Abstract][Full Text] [Related]
7. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.
Xu B; Chevarie-Davis M; Chevalier S; Scarlata E; Zeizafoun N; Dragomir A; Tanguay S; Kassouf W; Aprikian A; Brimo F
Hum Pathol; 2014 Mar; 45(3):488-97. PubMed ID: 24406017
[TBL] [Abstract][Full Text] [Related]
8. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.
van Leenders GJ; Boormans JL; Vissers CJ; Hoogland AM; Bressers AA; Furusato B; Trapman J
Mod Pathol; 2011 Aug; 24(8):1128-38. PubMed ID: 21499236
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
[TBL] [Abstract][Full Text] [Related]
10. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
[TBL] [Abstract][Full Text] [Related]
13. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
14. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract][Full Text] [Related]
15. Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion.
Sung JY; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Kang SY; Choi YL; Kwon GY
J Clin Pathol; 2016 Jul; 69(7):586-92. PubMed ID: 26670747
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
17. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
18. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.
Lippolis G; Edsjö A; Stenman UH; Bjartell A
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):145-50. PubMed ID: 23459095
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
[TBL] [Abstract][Full Text] [Related]
20. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.
Graff RE; Pettersson A; Lis RT; Ahearn TU; Markt SC; Wilson KM; Rider JR; Fiorentino M; Finn S; Kenfield SA; Loda M; Giovannucci EL; Rosner B; Mucci LA
Am J Clin Nutr; 2016 Mar; 103(3):851-60. PubMed ID: 26817504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
